This Week in Pulmonary — Jun 22, 2026

Welcome to This Week in Pulmonary. This week we are covering nine notable papers spanning chronic airway diseases and systemic intersections, advanced diagnostics and global health vulnerabilities, and clinical management frameworks. Let's dive in.

We begin with new insights into how systemic conditions and systemic therapies intersect with chronic lung disease. In the journal Chest, researchers examined the prevalence of preserved ratio impaired spirometry, or PRISm, and restrictive spirometry patterns in people living with HIV [6]. Analyzing over one thousand well-treated individuals with HIV and twelve thousand matched population controls from Copenhagen, they found that those with HIV had a three-fold higher prevalence of both PRISm and restrictive patterns, affecting roughly ten percent of patients compared to just over three percent of controls. This association remained strong even in non-smokers and after adjusting for traditional cardiovascular risk factors, suggesting that these spirometric impairments represent distinct, underrecognized manifestations of HIV-associated lung injury. Meanwhile, a retrospective cohort study in Respiratory Medicine explored the pulmonary safety and potential benefits of interleukin-17 inhibitors, which are commonly used for psoriasis [8]. Utilizing a target trial emulation framework with over twenty-eight thousand matched pairs, the investigators found that patients receiving interleukin-17 inhibitors actually had a lower risk of developing chronic obstructive pulmonary disease, at two point five percent compared to three point six percent in untreated controls. They also observed significant risk reductions for respiratory infections, respiratory failure, persistent asthma, and oxygen dependence, with ixekizumab demonstrating the most pronounced risk reductions, providing reassuring safety data and a potential therapeutic signal for future prospective trials. Finally, in ERJ Open Research, the China Asthma Data Registry Project evaluated over twenty thousand asthmatic patients across fifty-eight tertiary hospitals, revealing substantial gaps in care [10]. Nearly twenty-three percent of patients had completely uncontrolled asthma, and forty-five percent experienced at least one exacerbation annually, yet only about twenty-one percent had used inhaled corticosteroids in the previous year. Notably, cough was the most common symptom, and severe cough was an independent predictor of poor asthma control, with the predictive strength being paradoxically stronger in inhaled corticosteroid users than in non-users, emphasizing the critical need to specifically target cough-predominant phenotypes in clinical practice.

Next, we turn to critical diagnostic delays, acute support mechanisms, and the health of vulnerable populations. A retrospective cohort study published in Thorax evaluated the social and health factors associated with diagnosing tuberculosis after death in England, representing the ultimate diagnostic delay [1]. Out of over seventy-two thousand cases notified over a twelve-year period, five hundred and seventy-four were diagnosed postmortem, averaging nearly one case per week. The odds of a postmortem diagnosis increased dramatically with age, reaching an adjusted odds ratio of over eighty-five in patients aged ninety or older, and were also significantly higher in young children under five, men, those born in the United Kingdom, and individuals with alcohol or drug misuse. Conversely, prior BCG vaccination and having a purely pulmonary presentation were associated with lower odds of a postmortem diagnosis, highlighting the necessity of recognizing postmortem diagnoses as preventable events and targeting vulnerable demographics to close diagnostic gaps. This need for equitable care is echoed in a progress review from the UCL-Lancet Commission on Migration and Health, which warns that despite rising global migration and forced displacement, progress toward implementing inclusive healthcare policies has been slow [9]. The authors call on political leaders to integrate health-inclusive policies for refugees and migrants, establish secure data systems to monitor progress, and fund research on how climate change impacts these mobile populations. For patients who do progress to severe respiratory or cardiac failure, a clinical review in the American Journal of Respiratory and Critical Care Medicine synthesizes the physiological mechanisms of extracorporeal life support [4]. The authors outline how advanced extracorporeal modalities stabilize gas exchange and modulate respiratory drive to enable lung-protective ventilation, thereby minimizing both ventilator-induced and patient self-inflicted lung injury, while also interrupting the dangerous cascade of hypoxemia-induced pulmonary vasoconstriction and right ventricular overload.

Our final theme focuses on practical frameworks for managing chronic diseases and advising patients on lifestyle modifications. In Respiratory Research, the REPEAT study investigated real-world persistence with antifibrotic treatments among nearly five thousand adults in France [5]. The twelve-month persistence rate was seventy point eight percent, with a median treatment duration of fourteen point one months. Crucially, a lack of structured follow-up, defined as having fewer than two pulmonary function tests during the study period, was strongly associated with a three-fold increase in the risk of treatment discontinuation. Conversely, regular outpatient visits, expert center follow-up, and proactive management such as temporary treatment interruptions were associated with higher persistence, pointing to modifiable healthcare steps clinicians can take to keep patients on life-prolonging therapies. For patients looking to maintain an active lifestyle, a practical guide in Chest addresses the common clinical dilemma of counseling patients on outdoor exercise during air pollution events, such as wildfire smoke episodes [7]. The authors propose a four-step framework anchored to the United States Air Quality Index: stratifying patients by cardiopulmonary vulnerability, interpreting local real-time pollutant data, applying risk-tailored threshold actions, and prescribing specific exercise modifications in timing, location, or intensity rather than recommending blanket exercise cessation. Lastly, a study in Chest utilized latent class analysis to phenotype nearly nine hundred adults with pulmonary arterial hypertension associated with congenital heart disease [3]. The analysis identified four distinct phenogroups in both pre- and post-tricuspid shunt populations. Notably, in the post-tricuspid group, a hyperkinetic phenotype uniquely benefited from combination targeted therapy, whereas in the pre-tricuspid group, older males with comorbidities experienced significantly higher mortality and attenuated treatment responses despite mild baseline hemodynamics, offering a more personalized approach to risk stratification than traditional anatomical classifications.

If you only have time for one paper this week, make it the French national REPEAT study on real-world antifibrotic persistence published in Respiratory Research [5]. This paper provides actionable, system-level strategies to improve drug persistence in patients with fibrosing interstitial lung disease, demonstrating that structured follow-up with regular pulmonary function testing and early supportive interventions can directly prevent premature treatment discontinuation.

Here are the key takeaways from this week in Pulmonary. First, well-treated individuals living with HIV have a three-fold higher prevalence of preserved ratio impaired spirometry and restrictive spirometry patterns compared to the general population, indicating a need for heightened vigilance and routine spirometric assessment. Second, interleukin-17 inhibitor therapy in patients with psoriasis is associated with a significantly reduced risk of incident chronic obstructive pulmonary disease and other adverse pulmonary outcomes, providing reassuring safety data for clinical practice. Third, severe cough remains a major driver of uncontrolled asthma in tertiary care settings, emphasizing that clinicians must prioritize cough-specific assessments and therapies. Fourth, maintaining structured follow-up with at least two pulmonary function tests annually is critical to preventing the discontinuation of antifibrotic therapies in patients with interstitial lung disease. Finally, when advising patients on exercising during poor air quality events, clinicians should use a risk-stratified approach based on the United States Air Quality Index to modify exercise parameters rather than issuing blanket recommendations to stop exercising.

That's your roundup for This Week in Pulmonary. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And for audio briefings on your own clinical questions and papers, visit audioscholar dot C C.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.